Once again Novartis’ cardio team looks to beat the odds using sketchy data and a familiar argument
Whenever a clinical trial team starts touting the “totality” of the data, you know they’re in trouble.
For Novartis’ Entresto (sacubitril/valsartan) team, that’s the early go-to position on their latest round of pivotal data for the blockbuster — which the pharma giant believes has megablockbuster potential. We already knew that Novartis’ team plans to field the drug to regulators in search of a label extension — but now we have a better idea of the hurdles it faces.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.